JP2003532640A5 - - Google Patents

Download PDF

Info

Publication number
JP2003532640A5
JP2003532640A5 JP2001574119A JP2001574119A JP2003532640A5 JP 2003532640 A5 JP2003532640 A5 JP 2003532640A5 JP 2001574119 A JP2001574119 A JP 2001574119A JP 2001574119 A JP2001574119 A JP 2001574119A JP 2003532640 A5 JP2003532640 A5 JP 2003532640A5
Authority
JP
Japan
Prior art keywords
apomorphine
patient
norapomorphine
administering
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001574119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003532640A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/040393 external-priority patent/WO2001076602A1/en
Publication of JP2003532640A publication Critical patent/JP2003532640A/ja
Publication of JP2003532640A5 publication Critical patent/JP2003532640A5/ja
Withdrawn legal-status Critical Current

Links

JP2001574119A 2000-04-07 2001-03-29 アポモルヒネ誘導体及びその使用方法 Withdrawn JP2003532640A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19565000P 2000-04-07 2000-04-07
US60/195,650 2000-04-07
PCT/US2001/040393 WO2001076602A1 (en) 2000-04-07 2001-03-29 Apomorphine derivatives and methods for their use

Publications (2)

Publication Number Publication Date
JP2003532640A JP2003532640A (ja) 2003-11-05
JP2003532640A5 true JP2003532640A5 (US07794700-20100914-C00152.png) 2005-05-26

Family

ID=22722192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001574119A Withdrawn JP2003532640A (ja) 2000-04-07 2001-03-29 アポモルヒネ誘導体及びその使用方法

Country Status (18)

Country Link
US (1) US6506765B2 (US07794700-20100914-C00152.png)
EP (1) EP1284735A4 (US07794700-20100914-C00152.png)
JP (1) JP2003532640A (US07794700-20100914-C00152.png)
KR (1) KR20030036157A (US07794700-20100914-C00152.png)
CN (1) CN1471395A (US07794700-20100914-C00152.png)
AU (1) AU2001255818A1 (US07794700-20100914-C00152.png)
BG (1) BG107217A (US07794700-20100914-C00152.png)
BR (1) BR0109515A (US07794700-20100914-C00152.png)
CA (1) CA2405419A1 (US07794700-20100914-C00152.png)
CZ (1) CZ20023637A3 (US07794700-20100914-C00152.png)
HU (1) HUP0301773A3 (US07794700-20100914-C00152.png)
IL (1) IL151614A0 (US07794700-20100914-C00152.png)
MX (1) MXPA02009904A (US07794700-20100914-C00152.png)
NO (1) NO20024806D0 (US07794700-20100914-C00152.png)
PL (1) PL361672A1 (US07794700-20100914-C00152.png)
SK (1) SK15772002A3 (US07794700-20100914-C00152.png)
WO (1) WO2001076602A1 (US07794700-20100914-C00152.png)
ZA (1) ZA200207489B (US07794700-20100914-C00152.png)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
BR0308567A (pt) * 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
WO2004069167A2 (en) * 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
AU2004228757A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
PT1937276E (pt) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Gel de testosterona melhorado e método para a sua utilização
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
SG11202004461YA (en) 2017-11-24 2020-06-29 H Lundbeck As New catecholamine prodrugs for use in the treatment of parkinson's disease
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
ES2194867T3 (es) 1993-03-26 2003-12-01 Franciscus Wilhelmus He Merkus Composiciones farmaceuticas para la administracion intranasal de apomorfina.
KR100374924B1 (ko) 1994-04-22 2003-07-22 퀸스 유니버시티 엣 킹스톤 남성발기기능장애를회복시키고진단하기위한설하용량형
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
ATE211906T1 (de) 1996-03-12 2002-02-15 Alza Corp Zusammensetzung und dosisform mit einem opioid- antagonisten
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
JP4754067B2 (ja) 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
MXPA01000275A (es) * 1998-06-22 2002-04-24 Univ Kingston Metodo y composiciones para el tratamiento o alivio de disfunciones sexuales femeninas.
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
JP2002544221A (ja) * 1999-05-13 2002-12-24 ユニハート コーポレーション アポコデインおよび/またはその誘導体を含んでなる医薬組成物

Similar Documents

Publication Publication Date Title
JP2003532640A5 (US07794700-20100914-C00152.png)
JP2021063088A5 (US07794700-20100914-C00152.png)
JP2005526107A5 (US07794700-20100914-C00152.png)
JP2003501488A5 (US07794700-20100914-C00152.png)
JP2003535094A5 (US07794700-20100914-C00152.png)
JP2012525393A5 (US07794700-20100914-C00152.png)
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
JP2001525359A5 (US07794700-20100914-C00152.png)
JP2020507589A5 (US07794700-20100914-C00152.png)
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
JP2002363097A5 (US07794700-20100914-C00152.png)
JP2008523098A5 (US07794700-20100914-C00152.png)
JP2002508361A5 (US07794700-20100914-C00152.png)
JP2004534769A5 (US07794700-20100914-C00152.png)
JP2004525142A5 (US07794700-20100914-C00152.png)
JP2019515908A5 (US07794700-20100914-C00152.png)
JP2003509349A5 (US07794700-20100914-C00152.png)
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
JP2001526218A5 (US07794700-20100914-C00152.png)
EP1153924A3 (en) Substituted 1,3-oxathiolanes with antiviral properties
JP2005525991A5 (US07794700-20100914-C00152.png)
JP2003520208A5 (US07794700-20100914-C00152.png)
JP2005526773A5 (US07794700-20100914-C00152.png)
JP2002509154A5 (US07794700-20100914-C00152.png)